Kyle W Ruffing, MD, FAAN : Research

Neuromuscular Medicine Specialist

4.7

Active clinical trials

EDG-5506-203 MESA is an open-label extension study to assess the long-term effect of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults and adolescents with Becker muscular dystrophy

Investigator: Kyle W Ruffing
Status: Accepting Candidates
Ages: N/A - N/A
Sexes: Male

My publications

4 publications

2026

Clinical Reasoning: A 55-Year-Old Man With Rapidly Progressive Weakness and Numbness.

Neurology

PubMed • Publisher's site

2026

Paucibacillary leprosy presenting as fibular neuropathy: A case of autochthonous zoonotic exposure in endemic Florida.

PLoS neglected tropical diseases

PubMed • Publisher's site

2026

Novel FHL1 Mutation Associated With Reducing Body Myopathy.

Cureus

PubMed • Publisher's site

2026

Head trauma and environment progression of amyotrophic lateral sclerosis: long-term data from the National ALS Registry.

BMJ neurology open

PubMed • Publisher's site

Active clinical trials

My publications

Filter publications

Clinical Reasoning: A 55-Year-Old Man With Rapidly Progressive Weakness and Numbness.

Paucibacillary leprosy presenting as fibular neuropathy: A case of autochthonous zoonotic exposure in endemic Florida.

Novel FHL1 Mutation Associated With Reducing Body Myopathy.

Head trauma and environment progression of amyotrophic lateral sclerosis: long-term data from the National ALS Registry.